Published in J Clin Microbiol on March 19, 2010
Novel selective medium for isolation of Staphylococcus lugdunensis from wound specimens. J Clin Microbiol (2014) 0.78
From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev (2008) 2.47
Staphylococcus lugdunensis, a common cause of skin and soft tissue infections in the community. J Clin Microbiol (2009) 2.11
Staphylococcus lugdunensis in several niches of the normal skin flora. Clin Microbiol Infect (2009) 1.50
The "surreptitious Staphylococcus": Staphylococcus lugdunensis endocarditis in a child. Pediatr Infect Dis J (2002) 1.07
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect (2011) 17.47
New method for the serological grouping of Streptococci with specific antibodies adsorbed to protein A-containing staphylococci. Infect Immun (1973) 7.92
Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect (2006) 2.82
EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect (2011) 2.65
Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother (1984) 2.21
Epidural versus non-epidural or no analgesia in labour. Cochrane Database Syst Rev (2005) 2.21
ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect (2014) 2.13
European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect (2004) 1.95
Evaluation of a cefoxitin 30 microg disc on Iso-Sensitest agar for detection of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (2003) 1.91
Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother (1992) 1.90
Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect (2013) 1.65
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect (2012) 1.53
Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother (2009) 1.51
The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother (1993) 1.50
Staphylococcus lugdunensis in several niches of the normal skin flora. Clin Microbiol Infect (2009) 1.50
Genetic basis of resistance to fusidic acid in staphylococci. Antimicrob Agents Chemother (2007) 1.48
Norfloxacin treatment of salmonellosis does not shorten the carrier stage. Scand J Infect Dis (1990) 1.46
Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand (2004) 1.45
Idiopathic pulmonary fibrosis in infants: good prognosis with conservative management. Arch Dis Child (2000) 1.39
Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill (2011) 1.34
Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother (2010) 1.34
Survival and quality of life of cystic fibrosis patients before and after heart-lung transplantation. Transplant Proc (1991) 1.33
Phenotypic detection of methicillin resistance in Staphylococcus aureus by disk diffusion testing and Etest on Mueller-Hinton agar. J Clin Microbiol (2006) 1.33
Methods for identifying methicillin resistancein Staphylococcus aureus. J Hosp Infect (2001) 1.32
Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection. J Clin Microbiol (1997) 1.28
Evaluation of cefoxitin 5 and 10 microg discs for the detection of methicillin resistance in staphylococci. J Antimicrob Chemother (2005) 1.28
Evaluation of four selective agars and two enrichment broths in screening for methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2008) 1.26
Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol (2010) 1.24
Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid. Scand J Infect Dis (2002) 1.19
Letter: Prolonged excretion of gentamicin in a patient with umimpaired renal function. Lancet (1975) 1.16
Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand J Infect Dis Suppl (1997) 1.16
A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes. Clin Microbiol Infect (2003) 1.15
Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother (1994) 1.13
Passive smoking and impaired lung function in cystic fibrosis. Arch Dis Child (1994) 1.11
Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn's disease. Eur J Clin Pharmacol (1977) 1.10
Who is referred to neurology clinics?--the diagnoses made in 3781 new patients. Clin Neurol Neurosurg (2010) 1.08
Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Ir Med J (2007) 1.07
Symptoms 'unexplained by organic disease' in 1144 new neurology out-patients: how often does the diagnosis change at follow-up? Brain (2009) 1.06
Heart-lung transplantation for end-stage respiratory disease in patients with cystic fibrosis at Papworth Hospital. J Heart Lung Transplant (1994) 1.06
Evaluation of spiramycin as a therapeutic agent for elimination of nasopharyngeal pathogens. Possible use of spiramycin for middle ear infections and for gonococcal and meningococcal nasopharyngeal carriage. Scand J Infect Dis (1978) 1.06
Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2011) 1.06
Diversity among 2481 Escherichia coli from women with community-acquired lower urinary tract infections in 17 countries. J Antimicrob Chemother (2005) 1.03
Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database Syst Rev (2007) 1.03
Staphylococcus aureus resistant to fusidic acid among Swedish children: a follow-up study. Scand J Infect Dis (2006) 0.99
Tetracycline-resistant group A streptococci and pneumococci. Scand J Infect Dis (1972) 0.99
Antimicrobial susceptibility in Escherichia coli of human and avian origin--a comparison of wild-type distributions. Clin Microbiol Infect (2009) 0.99
Markers of experimental acute inflammation in the Wistar Han rat with particular reference to haptoglobin and C-reactive protein. Arch Toxicol (2003) 0.97
Endobronchial tumours in childhood. Eur J Radiol (1998) 0.97
Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev (2000) 0.97
Effect of acute induced metabolic alkalosis on 800-m racing time. Med Sci Sports Exerc (1983) 0.96
Isolation of a malonyl-CoA-sensitive CPT/beta-oxidation enzyme complex from heart mitochondria. Biochemistry (1990) 0.94
Longstanding post-therapeutic gentamicin serum and urine concentrations in patients with unimpaired renal function. A pharmacokinetic evaluation. J Antimicrob Chemother (1978) 0.93
Neurology out-patients with symptoms unexplained by disease: illness beliefs and financial benefits predict 1-year outcome. Psychol Med (2009) 0.92
Determination of chloramphenicol in serum and cerebrospinal fluid with high-pressure liquid chromatography. J Antimicrob Chemother (1978) 0.92
Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J Antimicrob Chemother (2013) 0.90
Kawasaki disease associated with varicella: a rare association. Br J Dermatol (1999) 0.89
Standard and real-time multiplex PCR methods for detection of trimethoprim resistance dfr genes in large collections of bacteria. Clin Microbiol Infect (2007) 0.89
Validation of EUCAST zone diameter breakpoints against reference broth microdilution. Clin Microbiol Infect (2013) 0.89
Heart and lung transplantation for terminal cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg (1991) 0.88
Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates. Clin Microbiol Infect (2012) 0.88
Mecillinam and ampicillin separately or combined in gram-negative septicemia. Infection (1980) 0.87
Associated antimicrobial resistance in Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes. Clin Microbiol Infect (2008) 0.87
Multiple-compartment pharmacokinetics of tobramycin. J Antimicrob Chemother (1978) 0.87
Trends in passive smoking in cystic fibrosis, 1993-1998. Pediatr Pulmonol (2001) 0.86
Widespread implementation of EUCAST breakpoints for antibacterial susceptibility testing in Europe. Euro Surveill (2015) 0.85
Introduction to tripartite meeting report (convenors: Dr Nigel Baber and Prof. Ros Smyth): towards establishing optimal doses for drugs prescribed to children. Br J Clin Pharmacol (2005) 0.85
Chlorhexidine for prevention of neonatal colonization with group B streptococci. II. Chlorhexidine concentrations and recovery of group B streptococci following vaginal washing in pregnant women. Eur J Obstet Gynecol Reprod Biol (1983) 0.85
[Antibiotic resistance. A real threat in Sweden too]. Lakartidningen (1997) 0.84
Total hip joint arthroplasty with gentamicin-impregnated cement. A clinical study of gentamicin excretion kinetics. Clin Orthop Relat Res (1983) 0.84
Chlorhexidine for prevention of neonatal colonization with group B streptococci. I. In vitro effect of chlorhexidine on group B streptococci. Eur J Obstet Gynecol Reprod Biol (1983) 0.84
Invasive pneumococcal disease in patients with an underlying pulmonary disorder. Clin Microbiol Infect (2013) 0.84
Emergence of clonally related multidrug resistant Haemophilus influenzae with penicillin-binding protein 3-mediated resistance to extended-spectrum cephalosporins, Norway, 2006 to 2013. Euro Surveill (2014) 0.83
Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients. Clin Chem (1990) 0.83
Antibiotic prescription practices, consumption and bacterial resistance in a cross section of Swedish intensive care units. Acta Anaesthesiol Scand (2002) 0.83
Oral steroids for cystic fibrosis. Cochrane Database Syst Rev (2000) 0.83
Netilmicin: clinical pharmacokinetics and aspects on dosage schedules. An overview. Scand J Infect Dis Suppl (1980) 0.82
Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. Eur J Cancer (2010) 0.82
The need for European professional standards and the challenges facing clinical microbiology. Eur J Clin Microbiol Infect Dis (2010) 0.82
Antimicrobial resistance in Escherichia coli in urine samples from children and adults: a 12 year analysis. Acta Paediatr (2004) 0.81
Chlorhexidine for prevention of neonatal colonization with group B streptococci. III. Effect of vaginal washing with chlorhexidine before rupture of the membranes. Eur J Obstet Gynecol Reprod Biol (1985) 0.81
Extending the clinical research network approach to all of healthcare. Ann Oncol (2011) 0.81
Phonological activation in anaphoric lexical access (ALA). Brain Lang (1999) 0.81
Vancomycin and netilmicin as first line treatment of peritonitis in CAPD patients. J Antimicrob Chemother (1985) 0.81
Some causes for variation in aminoglycoside plate assays. J Antimicrob Chemother (1980) 0.80
Early graft function following heart and lung transplantation. Transpl Int (1989) 0.80
[A boy suffering from SLT associated hemolytic uremic syndrome]. Lakartidningen (1989) 0.79
Update of microbial problems in pediatric otorhinolaryngology: plenary session. Int J Pediatr Otorhinolaryngol (1999) 0.78
Intensive care management of children following heart and heart-lung transplantation. Intensive Care Med (1990) 0.78
Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review. J R Soc Med (1997) 0.78
Fetal vibroacoustic stimulation for facilitation of tests of fetal wellbeing. Cochrane Database Syst Rev (2001) 0.78
Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis. Thorax (2000) 0.77
Utilization of intracellular acylcarnitine pools by mononuclear phagocytes. Biochim Biophys Acta (1994) 0.77
Development of EUCAST zone diameter breakpoints and quality control range for Staphylococcus aureus with ceftaroline 5-μg disk. Eur J Clin Microbiol Infect Dis (2014) 0.77
Some factors affecting accuracy of Canadian Home Fitness Test scores. Can J Appl Sport Sci (1979) 0.77
Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev (2000) 0.77
Vibroacoustic stimulation for fetal assessment in labour in the presence of a nonreassuring fetal heart rate trace. Cochrane Database Syst Rev (2005) 0.77